Scholars@Duke
Journal cover image

Prespecified third interim analysis of the darolutamide observational (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC): European subgroup analysis

Publication ,  Conference
Briganti, A; Luz, M; Yu, E; Pieczonka, C; Murphy, D; Armstrong, AJ; Hellmis, E; Kretz, T; Spiegelhalder, P; Adorjan, P; Ghadessi, M; Suzuki, H ...
Published in: EUROPEAN UROLOGY
2025

Duke Scholars

Andrew John Armstrong
Author Andrew John Armstrong Medicine, Medical Oncology

Published In

EUROPEAN UROLOGY

EISSN

1873-7560

ISSN

0302-2838

Publication Date

2025

Volume

87

Related Subject Headings

  • Urology & Nephrology
  • 3202 Clinical sciences
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Briganti, A., Luz, M., Yu, E., Pieczonka, C., Murphy, D., Armstrong, A. J., … Suzuki, H. (2025). Prespecified third interim analysis of the darolutamide observational (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC): European subgroup analysis. In EUROPEAN UROLOGY (Vol. 87).
Briganti, A., M. Luz, E. Yu, C. Pieczonka, D. Murphy, A. J. Armstrong, E. Hellmis, et al. “Prespecified third interim analysis of the darolutamide observational (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC): European subgroup analysis.” In EUROPEAN UROLOGY, Vol. 87, 2025.
Briganti A, Luz M, Yu E, Pieczonka C, Murphy D, Armstrong AJ, Hellmis E, Kretz T, Spiegelhalder P, Adorjan P, Ghadessi M, Verholen F, Suzuki H. Prespecified third interim analysis of the darolutamide observational (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC): European subgroup analysis. EUROPEAN UROLOGY. 2025.
Journal cover image

Published In

EUROPEAN UROLOGY

EISSN

1873-7560

ISSN

0302-2838

Publication Date

2025

Volume

87

Related Subject Headings

  • Urology & Nephrology
  • 3202 Clinical sciences
  • 1103 Clinical Sciences